Literature DB >> 6185233

In vivo tyrosine phosphorylations of the Abelson virus transforming protein are absent in its normal cellular homolog.

A S Ponticelli, C A Whitlock, N Rosenberg, O N Witte.   

Abstract

The transforming gene product of the Abelson murine leukemia virus (A-MuLV) is a phosphoprotein encoded by combined viral and cellular sequences. Previous work has shown the existence of a serologically crossreactive normal cellular phosphoprotein called NCP150. We have utilized two-dimensional phosphopeptide mapping and phosphoamino acid analysis to compare the structures of NCP150 and wild-type and mutant forms of the A-MuLV protein labeled in vivo with 32P-orthophosphate. This analysis demonstrated clear homology between NCP150 and wild-type A-MuLV protein, but a number of phosphorylation differences were seen. Among them, two specific tyrosine phosphorylations present in all transformation-competent Abelson proteins were not observed in NCP150. No other phosphotyrosine-containing peptides were detected. In addition, transformation-defective mutants isolated from either the P120 or P160 wild-type strain lack phosphotyrosine-containing peptides. Double-infection studies with such transformation-defective and transformation-competent A-MuLV strains show that Abelson viral proteins may be substrates for their own tyrosine-specific kinase activity in vivo. These observations suggest that the phosphotyrosine kinase activity of the abl region may be controlled, and may function, differently in its viral and cellular forms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6185233     DOI: 10.1016/0092-8674(82)90458-5

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  21 in total

1.  The noncatalytic src homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated cellular proteins with high affinity.

Authors:  B J Mayer; P K Jackson; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

2.  Carboxyl-terminal determinants of Abelson protein important for lymphoma induction.

Authors:  K Parmar; R C Huebner; N Rosenberg
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

Review 3.  Following the cytokine signaling pathway to leukemogenesis: a chronology.

Authors:  Kendall A Smith; James D Griffin
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

4.  A membrane-associated, carbohydrate-modified form of the v-abl protein that cannot be phosphorylated in vivo or in vitro.

Authors:  S M Watanabe; N E Rosenberg; O N Witte
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

5.  En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.

Authors:  A J Muller; A M Pendergast; K Parmar; M H Havlik; N Rosenberg; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

6.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

7.  Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity.

Authors:  J B Konopka; R L Davis; S M Watanabe; A S Ponticelli; L Schiff-Maker; N Rosenberg; O N Witte
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

8.  Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase.

Authors:  B J Mayer; D Baltimore
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

9.  Vasodilator-stimulated phosphoprotein regulates proliferation and growth inhibition by nitric oxide in vascular smooth muscle cells.

Authors:  Lihua Chen; Günter Daum; Kanchan Chitaley; Scott A Coats; Daniel F Bowen-Pope; Martin Eigenthaler; Naresh R Thumati; Ulrich Walter; Alexander W Clowes
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-06-03       Impact factor: 8.311

10.  Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.

Authors:  J B Konopka; S M Watanabe; J W Singer; S J Collins; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.